Chat with Dr. Thor Halfdarnason, Mayo Clinic - February 19, 2023

Dr. Thor Halfdarnason joined us in February 19, 2023  to have an interactive chat with members of Northwoods NETS. He discussed the latest treatments, research, and trials for the treatment of neuroendocrine tumors and neuroendocrine carcinoma. Click here for a PDF of his presentation. Northwoods NETS is a neuroendocrine cancer support group based out of the Twin Cities in Minnesota. We are a 501(c)3 nonprofit that provides support for people

Dr. Thor presents the latest in NET research and treatments

Please join us on February 19, 2023, for our bi-monthly “Zoom” support meeting. The meeting will begin at 1:00 pm CST so please log in a few minutes early. We are pleased that Dr. Thor Halfdanarson from Mayo Clinic will be joining us for the first hour to discuss new research and treatments that are available to treat neuroendocrine tumors and cancers. Are you curious about new trials? Want more

NET Cancer Awareness Day Proclamation - Minnesota 2022

Governor Walz Proclaims NET Cancer Awareness Day We are pleased and grateful to announce that Governor Tim Walz has proclaimed Thursday, November 10th as NET Cancer Awareness Day. See the proclamation at our website. I-35W Bridge Lights Up For NET Cancer Day MN-DOT has agreed, once again, to light the I35-W Saint Anthony Falls Bridge in honor of NET Cancer Day. After sundown, the bridge will be lit up in

URGENT ACTION NEEDED: Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772)

Action Requested by November 1, 2019 On October 18, 2019, an opinion piece that NorCal CarciNET Community’s Josh Mailman opinion article (“CMS policy shouldn’t penalize those with rare disease”) was published by The Hill,  The opinion piece highlighted the challenges with the current method that Medicare/CMS use to pay for radiopharmaceuticals. This webpage provides more information on how this will impact NET patients and providers along with a  tool for those that are

M. Sue O'Dorisio

University of Iowa Holden Comprehensive Cancer Center is the first U.S. cancer center to be designated a Neuroendocrine Tumor Center of Excellence by the European Neuroendocrine Tumor Society (ENETS). In making the award to the Iowa team in early March, ENETS listed its criteria for the distinction, including The Holden team’s advanced interdisciplinary approach for diagnosing neuroendocrine tumor (NET) patients The quality and breadth of the team’s medical treatments for NETS